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Abstract
Introduction: The association of idiopathic inflammatory myositis (IIM) and malignancies has been reported, but rarely 
in Asian countries. Our aim was to investigate the risk of cancer among IIM patients without a prior history of 
malignancies, in Taiwan.
Methods: We conducted a nationwide cohort study of 1,012 patients with dermatomyositis (DM) and 643 patients 
with polymyositis (PM), but without prior history of malignancies, utilizing the National Health Insurance Database 
from 1997 to 2007. Standardized incidence ratios (SIRs) of cancers were analyzed.
Results: A total of 95 cancers (9.4%) in DM and 33 cancers (4.4%) in PM were identified. Overall cancer risk was 
significantly elevated in DM patients (SIR = 5.11, 95% confidence interval [CI] = 5.01 to 5.22) and PM patients (SIR = 2.15, 
95% CI = 2.08 to 2.22). Most cancers were detected in the first year of observation. The risk of cancer decreased with 
observation time, yet remained elevated compared with the general population in both study groups after 5 years of 
follow-up. DM was associated with sustained elevated risk of cancers in every age group, whereas the risk of cancer in 
PM was highest in younger patients and decreased with age. DM patients were at the greatest risk of cancers of the 
nasopharynx, lungs and hematopoietic malignancies.
Conclusions: Patients with IIM are at increased risk for cancer and should receive age-appropriate and gender-
appropriate malignancy evaluations, with additional assessment for nasopharyngeal, lung and hematologic 
malignancy following diagnosis, and with continued vigilance for development of cancers in follow-up.
Introduction
The association of malignancies with dermatomyositis
(DM) or polymyositis (PM) has been studied extensively
both in Caucasian and Asian populations. Population-
based cohort studies in Denmark, Sweden and Finland
[1,2] have demonstrated that DM, and to a lesser extent
PM, carries elevated risk of comorbid cancers, in which
cancers of the ovary, lung, pancreas, stomach and urinary
bladder, as well as hematologic cancers including non-
Hodgkin's lymphoma and Hodgkin's lymphoma, are the
most relevant [1]. Most comorbid cancers are detected
within the first year of diagnosis of idiopathic inflamma-
tory myositis (IIM) [1,2]. A thorough physical and labora-
tory work-up for early detection of these cancers is
therefore strongly recommended after diagnosis of IIM.
The epidemiologic data on IIM-associated cancer
types, however, are scarce and varied in Asian popula-
tions. Breast cancer, stomach cancer and nasopharyngeal
cancer (NPC) have been reported to be more commonly
associated with DM in Korea [3]. Studies in Singapore,
Hong Kong, southeastern China and Taiwan have
revealed that NPC is the most common cancer associated
with DM [4-7]. Our recent population-based, case-con-
trol study demonstrated that DM and PM patients are
associated with a sixfold to 10-fold increased chance of
cancer compared with control subjects. About two-thirds
of comorbid cancers occur after diagnosis of IIM [8].
The present study aimed to investigate the risk of spe-
cific cancer types among a DM/PM cohort by IIM sub-
type, age at diagnosis, and follow-up time, utilizing
analyses of standardized incidence ratios (SIRs).
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Materials and methods
Data sources
The present study was based on data from the National
Health Insurance Research Database released by the
National Health Research Institute. Taiwan began its
National Health Insurance program in 1995 to finance
healthcare for all of its residents. There are currently >25
million enrollees in the program, representing approxi-
mately 99% of Taiwan's entire population. The database
comprises comprehensive information on insured sub-
jects, such as demographic data, dates of clinical visits,
diagnostic codes, details of prescriptions, and expendi-
ture amounts. This database has been the source of many
epidemiological studies published in peer-reviewed jour-
nals [8-13].
International Classifications of Disease-9 (ICD-9)
codes were used to define diseases during the study
period. Personal information, including family history,
lifestyle and habits such as smoking and alcohol use, was
not available from the National Health Insurance
Research Database.
Study subjects
All enrollees were obtained from the Registry of Cata-
strophic Illness Database, a subpart of the National
Health Insurance Research Database. The insured who
suffer from major diseases can apply for a catastrophic ill-
ness certificate, which grants exemption from co-pay-
ment. DM, PM and cancer are statutorily included in the
catastrophic illness category. Both outpatient and inpa-
tient claims of beneficiaries with a catastrophic illness
registry are collected in the catastrophic illness profile
and distributed as a package.
Application of catastrophic illness certificate for DM
and PM requires a thorough clinical and laboratory sur-
vey that fulfills the diagnostic criteria proposed by Bohan
and Peter [14,15]. The diagnostic criteria for DM and PM
include: symptoms of proximal muscle weakness; abnor-
mal results on electromyography; abnormal results on
muscular biopsy; elevated serum levels of muscle enzyme
(creatine kinase), lactate dehydrogenase, aspartate
transaminase and alanine transaminase; and typical skin
rash compatible with DM. Only those with diagnosis of
definite DM or definite PM are issued a catastrophic ill-
ness certificate.
The enrollees with DM (ICD-9 code 710.3) and with
PM (ICD-9 code 710.4) were followed up between 1 Janu-
ary 1997 and 31 December 2007. Amyopathic DM and
inclusion body myositis were not identified due to a lack
of specific diagnostic codes.
As the dataset used in this study consists of de-identi-
fied secondary data released to the public for research
purposes, the study was exempt from full review by the
Institutional Review Board.
Identification of cancer cases
To apply for a cancer catastrophic illness certificate, cyto-
logical or pathological reports or evidence such as addi-
tional laboratory and image studies supporting the
diagnosis of cancer - including tumor marker surveys, X-
ray scan, bone scan, computed tomography scan or mag-
netic resonance imaging scan - should be provided. We
excluded those patients with in situ malignancies because
in situ malignant diseases do not qualify for a cata-
strophic illness certificate. The diagnostic codes of malig-
nancies were defined as those from code 140 to code
208.91 in the ICD-9 Clinical Modification format.
Cancer risk analysis
All enrolled study subjects were followed up until a first-
time diagnosis of cancer (except malignancy in situ or
metastatic cancers), death, the end of follow-up in the
medical records, the end of the observation period, or the
end of 2007. SIRs of cancers were analyzed. Stratified
analyses according to age at diagnosis, gender, and years
of follow-up were conducted.
Statistical analysis
The demographic data of the study population were first
analyzed. Follow-up for each patient with myositis began
at the date of diagnosis and ended at the date of censor-
ship - that is, the date of diagnosis of cancer, death or the
end of follow-up period - and was measured in numbers
of years. We examined the associations among DM, PM
and specific cancer types with SIRs. The SIR was calcu-
lated as follows: the number of cancer cases that arose
among DM or PM patients divided by the expected num-
ber of cancer cases according to national age-specific,
gender-specific, and period-specific cancer rates. Yearly
reports of cancer rates were obtained from the Taiwan
National Cancer Registry.
To assess the age effect on the relative risk of malignan-
cies, we analyzed the relative risks among those aged 0 to
19 years, 20 to 39 years, 40 to 59 years, 60 to 79 years, and
>80 years at myositis diagnosis. A further analysis was
performed to evaluate whether the association of malig-
nancies varied according to the time after myositis diag-
nosis. We divided the follow-up time into four periods: ≤
1 year, 1 to 2 years, 2 to 5 years and ≥ 5 years.
The SAS statistical package (SAS System for Windows,
version 9.1; SAS Institute, Cary, NC, USA) and SPSS sta-
tistics (SPSS Statistics for Windows, version 15.0; SPSS
Inc., Chicago, IL, USA) were used to perform the statisti-
cal analysis of the data in the present study.
Results
We identified a total of 1,012 patients with DM and 643
patients with PM, all without previous malignancies. The
mean ± standard deviation ages at diagnosis of DM andChen et al. Arthritis Research & Therapy 2010, 12:R70
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PM were 41.79 ± 18.96 years and 48.38 ± 16.63 years,
respectively. Among DM patients, 315 (31.13%) were
male and 697 (68.87%) were female. There were 199
(30.94%) male and 444 (69.06%) female patients in the PM
group (Table 1). The mean ± standard deviation follow-
up times for DM and PM were 5.09 ± 3.72 years and 5.05
± 3.42 years, respectively.
A total of 95 cancers (9.4%) in DM patients and 33 can-
cers (4.4%) in PM patients were identified after diagnosis
of myositis. The overall cancer risk was significantly ele-
vated among patients with DM (SIR = 5.11, 95% confi-
dence interval [CI] = 5.01 to 5.22), and to a lesser extent
among patients with PM (SIR 2.15, 95% CI = 2.08 to 2.22)
(Table 2). The SIRs for men and women with DM were
5.44 (95% CI = 5.28 to 5.62) and 5.10 (95% CI = 4.96 to
5.23), respectively. Among PM patients, women had a
slightly higher risk than men for the development of
malignancies (SIR = 2.36 for women, SIR = 1.84 for men).
With regards to age, a bimodal-pattern distribution of
malignancy risk was observed among DM patients. DM
patients carried a sustained elevated risk of cancer in
every age group, especially in those younger than 60 years
and those older than 80 years (Table 2). For PM, younger
patients - especially those in their 20s - carried the high-
est risk of malignancies (SIR = 10.69, 95% CI = 9.99 to
11.60). The malignancy risk was reduced in patients with
older age at diagnosis (SIR = 2.61 in those 40 to 59 years
old, SIR = 1.91 in those ≥ 60 years old).
Comorbid malignant diseases were mostly detected fol-
lowing the first year of diagnosis, both in DM patients
and in PM patients (SIR = 21.30 and SIR = 6.70, respec-
tively). The risk of cancer decreased with follow-up time.
For example, the SIRs of cancer in DM during the 1 to 2
years and the 2 to 5 years of observation were 5.08 (95%
CI = 4.80 to 5.38) and 2.52 (95% CI = 2.38 to 2.66),
respectively. The risk of cancer in PM was reduced to the
expected incidence ratios of the general population after
2 years of follow-up (Table 2). The risk remained elevated
both in DM and PM patients after 5 years of observation,
however, with SIR = 1.37 (95% CI = 1.26 to 1.48) and SIR
= 1.99 (95% CI = 1.85 to 2.15), respectively.
The highest risks after diagnosis of DM were for NPC,
lung/mediastinum cancers, bone/joint cancers and lym-
phomas/leukemias. An elevated risk for many other can-
cers was also observed in DM patients (Table 3). For PM
patients, although there were limited cancer cases, the
greatest risks were for cancers of the bone and joint, the
brain, NPC and melanoma. Elevated risks of leukemia/
lymphomas and cancers of the uterus, oropharynx/lar-
ynx, urinary bladder, liver, colorectum and pancreas were
also observed in PM patients.
Discussion
A strong association between malignancy and myositis,
especially in DM patients, was observed in our study.
Most cancer cases were detected within the first year
after diagnosis. This observation was consistent with the
majority of reports in the literature, suggesting a parane-
oplastic nature for IIM. Aggressive surveillance for cancer
during that period may have resulted in a detection bias.
When cancer cases observed in the first 2 years were
excluded, a sustained elevated risk existed among DM
patients after 5 years of follow-up (SIR = 1.37) (Table 2) -
indicating a true link between these two diseases. The
risk of malignancy in PM was reduced to the expected
incidence ratio of the general population at 2 years of
observation. Although there appeared to be an increased
risk of cancer after 5 years of follow-up, the risk could not
be adequately assessed because of the small number of
cases, resulting in unstable estimates of risk. The lifelong
use of immunosuppressive drugs in both diseases may
also contribute to an elevated risk of cancer after years of
observation. The relationship between cancer and PM
needs further exploration. Overall, we suggest that physi-
cians continue to carry out cancer work-ups in myositis
patients for at least 5 years in IIM patients.
Only a few reports have focused on the age effect of
cancer risk among DM and PM patients. Hill and col-
Table 1: Age and gender distributions of the dermatomyositis and polymyositis study groups
Age Dermatomyositis group (n = 1,012) Polymyositis group (n = 643)
Number of 
cases
Male Female Number of 
cases
Male Female
<20 years 162 50 112 31 14 17
20 to 39 years 265 76 189 161 45 116
40 to 59 years 414 120 294 274 76 198
60 to 79 years 164 66 98 169 61 108
≥  8 0  y e a r s 734835
All 1,012 315 697 643 199 444Chen et al. Arthritis Research & Therapy 2010, 12:R70
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leagues indicated increased risks of cancer among DM
patients younger than 44 years (SIR = 2.2) and older than
45 years (SIR = 3.1) [1]. There was no such trend, how-
ever, in PM patients. Another report from Stockton and
colleagues indicated that cancer risk decreases with age
in DM patients, but not in PM patients [16]. Those
authors did not, however, further discuss the age effect.
In the present article, we demonstrated that the relative
risk of cancer in DM remains high in every age group,
whereas the risk of cancer in PM is highest in younger
patients and decreases with age. Since malignant diseases
increase with age among the general population (data not
presented), it is reasonable that the higher prevalence of
cancer cases among aged patients makes the difference in
incidence nonsignificant between older PM patients and
older people from the general population. Moreover, the
sustained elevated cancer risk in DM patients highlighted
the true link between DM and malignancies despite the
age effect.
A strong link between DM and NPC was highlighted in
the present study, with the SIR reaching as high as 140. A
pathogenetic correlation between cancers of the pharynx,
especially NPC, and DM has been proposed. NPC is
endemic to southeastern Asia and is related to the
chronic active infection of Epstein-Barr virus [17-19].
Three cases of chronic active Epstein-Barr virus infec-
tion-induced generalized myositis have been reported
[19]. Furthermore, Epstein-Barr virus has been detected
in lung specimens from patients with rapidly progressive
interstitial pneumonitis in PM/DM [20]. The immune
response to Epstein-Barr virus contributes to the coexis-
tence of DM/PM and NPC.
Other comorbid cancers commonly associated with
DM are cancers of the lungs/mediastinum, bone/joints
and kidney, as well as lymphoma and leukemia, with the
SIRs ranging from 5 to 24. In contrast to the most com-
monly associated cancers, such as those of the lungs and
ovaries, as well as lymphoma and leukemia, cases of myo-
sitis associated with renal or adrenal carcinomas have
rarely been reported [21-24]. Symptoms and laboratory
abnormalities of DM or PM have been reported to be
alleviated after surgical intervention for renal cancers
Table 2: Cancer incidence among dermatomyositis and polymyositis patients by age, gender and years of follow-up
Dermatomyositis group (n = 1,012) Polymyositis group (n = 643)
Observed Expected SIR (95% CI) Observed Expected SIR (95% CI)
Total 95 18.58 5.11 (5.01 to 5.22) 33 15.36 2.15 (2.08 to 2.22)
Age
<20 years 1 0.13 7.86 (6.26 to 9.36) 0 0.02 -
20 to 39 
years
8 1.11 7.20 (6.72 to 7.72) 7 0.65 10.69 (9.99 to 
11.60)
40 to 59 
years
55 6.67 8.25 (8.03 to 8.47) 13 4.98 2.61 (2.47 to 2.76)
60 to 79 
years
29 5.40 5.37 (5.18 to 5.57) 13 6.80 1.91 (1.81 to 2.02)
≥ 80 years 2 0.24 8.47 (7.22 to 9.57) 0 0.52 -
Gender
Male 39 7.16 5.44 (5.28 to 5.62) 12 6.51 1.84 (1.74 to 1.95)
Female 56 10.99 5.10 (4.96 to 5.23) 21 8.89 2.36 (2.26 to 2.47)
Follow-up
<1 years 64 3.00 21.30 (20.81 to 
21.86)
18 2.67 6.75 (6.43 to 7.06)
1 to 2 
years
12 2.36 5.08 (4.80 to 5.38) 3 2.30 1.31 (1.16 to 1.46)
2 to 5 
years
13 5.16 2.52 (2.38 to 2.66) 5 4.93 1.01 (0.93 to 1.11)
>5 years 6 4.39 1.37 (1.26 to 1.48) 7 3.51 1.99 (1.85 to 2.15)
Expected cancer cases were calculated by age-specific and gender-specific estimates of the general population in Taiwan 2006. CI, 
confidence interval; SIR, standardized incidence ratio.Chen et al. Arthritis Research & Therapy 2010, 12:R70
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Table 3: Incidence for specific cancer types after diagnosis of dermatomyositis and polymyositis
Cancer type Dermatomyositis group (n = 1,012) Polymyositis group (n = 643)
Observeda Expectedb SIR (95% CI) Observeda Expectedb SIR (95% CI)
Nasopharynx 30 0.21 139.94 (137.79 to 148.06) 2 0.16 12.71 (10.83 to 14.36)
Lungc 22 1.07 20.58 (19.71 to 21.44) 5 0.93 5.38 (4.92 to 5.87)
Breast 9 2.55 3.53 (3.30 to 3.77) 3 1.80 1.67 (1.48 to 1.87)
Uterus 0 - - 1 0.14 7.13 (5.81 to 8.69)
Uterine cervix 3 0.91 3.28 (2.93 to 3.68) 1 0.70 1.44 (1.16 to 1.74)
Ovaryc 2 0.38 5.33 (4.56 to 6.05) 0 - -
Lymphoma/
leukemia
4 0.16 24.70 (22.61 to 27.57) 1 0.13 7.78 (6.26 to 9.36)
Oropharynx and 
larynx
1 0.13 7.46 (6.26 to 9.36) 0 - -
Esophagus 1 0.33 3.06 (2.47 to 3.69) 0 - -
Liver/gall bladder 5 1.38 3.62 (3.31 to 3.96) 4 1.20 3.34 (3.01 to 3.68)
Colorectum 5 1.21 4.12 (3.78 to 4.51) 5 1.06 4.70 (4.31 to 5.15)
Stomach 1 0.97 1.03 (0.84 to 1.25) 0 - -
Pancreas 1 0.33 3.04 (2.47 to 3.69) 1 0.29 3.44 (2.81 to 4.19)
Kidney 3 0.51 5.93 (5.24 to 6.59) 1 0.45 2.22 (1.81 to 2.70)
Urinary bladder 2 0.49 4.05 (3.54 to 4.69) 2 0.44 4.59 (3.94 to 5.22)
Melanoma 1 0.23 4.33 (3.54 to 5.29)- 2 0.20 9.76 (8.66 to 11.49)
Bone/joint 1 0.07 14.87 (11.62 to 17.38) 2 0.05 39.64 (34.65 to 45.94)
Brain 0 - - 2 0.11 18.21 (15.75 to 20.88)
Thyroid 2 0.45 4.49 (3.85 to 5.10) 1 0.32 3.12 (2.54 to 3.80)
Metastatic 
cancersc
2 0.56 3.57 (3.09 to 4.10) 0 - -
aObserved cancer cases. bExpected cancer cases based on estimates of the general population in Taiwan, after age and gender adjustment. cLung, 
including lung and mediastinum; ovary, including ovary and fallopian tube; metastatic cancers, including cancers of ill-defined or unknown 
origin. CI, confidence interval; SIR, standardized incidence ratio.
[21,22]. In addition, there are rare occurrences of chond-
rosarcoma [25], osteosarcoma [26] and thyroid cancers
[27,28] in DM; yet the relationship between these dis-
eases and DM remains unclear.
Several population-based studies have indicated that
ovarian cancer is the most commonly associated malig-
nancy in female DM patients, with SIRs ranging from 8.2
to 32 [1,2,29,30], whereas the correlation between ovar-
ian cancer and PM is low. Ovarian carcinoma, however,
has not been addressed in studies from Asian populations
[4,6,31]. The risk of ovarian cancer was elevated in our
DM patients, although with a lower SIR (5.33) than in
western populations. Only two cases of ovarian cancer
were observed in our DM patients, and no cases were
o b s e r v e d  i n  o u r  P M  p a t i e n t s .  M o r d e l  a n d  c o l l e a g u e s
reviewed published case reports of ovarian cancer and
DM, and revealed that those with DM had a higher rate of
advanced ovarian adenocarcinoma (96%) than the gen-
eral female population with ovarian carcinoma (60 to
70%) [32].
Although there were limited numbers, diverse comor-
bid cancer types were associated with PM. The most sig-
nificantly associated cancers included cancers of the
bone/joints, nasopharynx and brain, and melanoma. The
correlation between these cancers and myositis, however,
remains unclear. Malignant melanoma-complicated DM/
PM has been frequently reported [33-37] and the devel-
opment of myositis in patients with melanoma may serve
as a poor prognostic marker [33,35]. Very few reports
have mentioned the correlation of these cancers in PM.
Actually, the true association of these cancers in PM is
doubtful and the risk of these cancers may be overesti-
mated in the present study due to the very small number
of cases.Chen et al. Arthritis Research & Therapy 2010, 12:R70
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An underlying mechanism of the association between
IIM and malignancies remains unclear. A model of cross-
over immunity for the development of cancer-associated
myositis has been proposed recently [38-40]. Common
antigenic myositis-specific autoantigens were expressed
in both tumor cells and undifferentiated myoblasts. Myo-
sitis-specific autoantigen expression in a nascent tumor
leads to the generation of both specific T cells and B cells
against those antigens, and then to successful anti-tumor
immunity. In a subset of patients, subsequent muscle
damage from a variety of potential causes (such as viral
infection, trauma, toxin exposure) may lead to muscle
damage and regeneration, and may reactivate immune
responses previously generated in the initial anti-tumor
response. The crossover immunity between tumor cells
and myofibroblasts may result in the parallel clinical
course of both diseases [41-44].
Until now, no population-based studies have provided
evidence for the causal relationship between IIM and
malignancies. A lower risk of cancer has been reported in
patients who previously received cytotoxic treatment for
inflammatory myopathies [29,45]. In the present article,
we demonstrated that the cancer risk in myositis patients
decreases with time - which favors the role of the inflam-
matory nature, rather than lifelong immunosuppressive
treatment, in the development of malignancies.
A limitation of the registry-based database is the possi-
ble misclassification of IIM. Due to the lack of specific
diagnostic codes, amyopathic DM and inclusion body
myositis - which have been reported to be associated with
malignancies - were not identified in our study. The risk
of cancer in IIM might therefore be underestimated. An
individually tailored screening for malignancy in IIM
patients has been recommended according to age, sex,
ethnicity and subset of IIM. In brief, we strongly suggest
conducting a thorough physical and laboratory check-up
for detecting malignancies for at least 5 years following
the diagnosis of IIM, especially in DM patients. In addi-
tion to the lungs and ovaries and lymphoma/leukemia,
we recommend that special attention be paid to the risk
of NPC and cancers of the renal system in DM and PM
patients. A nasopharyngeal endoscopy examination
should be routinely performed in all IIM patients. A thor-
ough physical examination including palpation of thyroid
glands, breast and lymph nodes will assist in the early
detection of occult cancers. Mammography, breast ultra-
sonography and the Papanicolaou test are essential in
female IIM patients. A more detailed history-taking and
physical examinations, including symptoms of headache,
neurologic signs, soreness of bones and joints, and skin
examination, should be mandatory in PM patients.
Conclusions
Patients with DM and PM carry an elevated risk of vari-
ous cancers in Taiwan. We suggest thorough physical and
laboratory tests for malignancies, especially those of the
nasopharynx, for at least 5 years of follow-up.
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